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While cautious criteria for selection of living kidney
donors are credited for favorable outcomes, recent
practice changes may include acceptance of less than
ideal donors. To characterize trends in donor accep-
tance, the Renal and Lung Living Donors Evaluation
(RELIVE) Study evaluated 8,951 kidney donors who do-
nated between 1963 and 2007 at three major U.S. trans-
plant centers. Over the study interval, there was an in-
crease in the percentage of donors >40 years old from
38% to 51%; donors >60 years varied between 1% and
4%. The proportion of donors with obesity increased
from 8% to 26% and with glucose intolerance from
9% to 25%. The percentage of hypertensive donors
was consistent (5–8%). Accepted donors ≥60 years old
were more likely to have obesity, glucose intolerance,
and/or hypertension compared to younger donors
(p < 0.0001). Our results demonstrate important trends
in acceptance of older and more obese donors. The
fraction of older donors accepted with glucose intoler-
ance or hypertension remains small and for the major-
ity includes mild elevations in glucose or blood pres-
sure that were previously classified as within normal
limits.
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Introduction
Failure of the deceased donor organ supply to meet the
needs of the growing number of end-stage renal dis-
ease (ESRD) patients awaiting transplantation motivates
donation from living donors. Data from national registries
and single center series suggest that the lifetime risks
of chronic kidney disease (CKD) and its associated co-
morbidities resulting from live kidney donation are mini-
mal (1–7). Historically, these excellent outcomes are be-
lieved to result, at least in part, from careful predona-
tion evaluation and conservative living donor eligibility
standards (8).
More recently, acceptance criteria at some transplant cen-
ters have relaxed to allow living kidney donation by older
individuals, and by donors with some known risk factors for
the eventual development of CKD including obesity, glu-
cose intolerance and treated hypertension (9–12). These
newer donor acceptance practices may be partially ex-
plained as the continuation of previous acceptance criteria
that were based upon older and less stringent definitions
of glucose intolerance, diabetes mellitus (13), and hyper-
tension (14). Acceptance of donors who might be consid-
ered less than ideal, due to relaxed eligibility criteria or
expanded diagnostic definitions of CKD risk factors, has
brought into question the applicability of prior living donor
outcome studies to current practices.
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The Renal and Lung Living Donors Evaluation (RELIVE)
Study is a research consortium funded by the National
Institute of Allergy, Immunology and Infectious Diseases
(NIAID), Health Resources and Services Administration
(HRSA), and National Heart Lung and Blood Institute
(NHLBI). RELIVE was established in 2006 to examine the
epidemiology of living kidney donation at three large U.S.
transplant centers (Mayo Clinic, Rochester, MN; Univer-
sity of Alabama at Birmingham, AL; and University of
Minnesota, Minneapolis, MN) with a Data Coordinating
Center (DCC) at the University of Michigan and Arbor Re-
search Collaborative for Health, Ann Arbor, MI. In this study,
our aim was to characterize temporal trends in living kidney
donor demographics, and potential risk factors for CKD at
the time of donation at the three RELIVE kidney transplant
centers over five decades.
Materials and Methods
The study was approved by the Institutional Review Boards (IRBs) at NIAID,
the study sites and the DCC.
There were 8,951 live kidney donations at the three study sites from 1963
to 2007. The medical record of each donor was manually abstracted for
predonation demographic information (date of birth, race, ethnicity), an-
thropometric measurements (height, weight, blood pressure), nicotine use,
prior or current diagnosis or treatment for hypertension or hyperlipidemia,
and laboratory data (fasting blood glucose, serum cholesterol and triglyc-
erides and serum creatinine). Blood pressure readings were collected from
up to three separate time points during the donor evaluation. Family his-
tory of hypertension, diabetes mellitus, kidney disease, transient ischemic
attack/stroke, or heart disease in the donor’s first degree relatives was
recorded if documented. Obesity was defined as a body mass index (BMI)
≥30 kg/m2. Glucose intolerance was defined as a fasting blood glucose
>100 mg/dL. Hypertension was defined as use of antihypertensive medi-
cations, a systolic blood pressure (SBP) ≥140 mmHg, or a diastolic blood
pressure (DBP) ≥90 mmHg, using the lowest of up to three recorded blood
pressure readings, as described above.
This study also used data from the Scientific Registry of Transplant Recipi-
ents (SRTR). The SRTR data system includes data on all donors, wait-listed
candidates and transplant recipients in the US, submitted by the members
of the Organ Procurement and Transplantation Network (OPTN). The Health
Resources and Services Administration (HRSA), U.S. Department of Health
and Human Services provides oversight to the activities of the OPTN and
SRTR contractors.
Statistical methods
We examined trends in the domains of interest over time, with the years of
donation grouped into quartiles: 1963–1974, 1975–1985, 1986–1996 and
1997–2007. We report means or percentages of donors with predonation
characteristics of interest in each interval. Quantile regression was used to
model the relation between year of donation and each of the five quantiles
(5th, 25th, 50th, 75th and 95th) of predonation characteristics (e.g., blood
pressure). Quantile regressions were limited to years in which there were
at least 20 donors with nonmissing data. Donors were also grouped based
on the presence or absence of predonation obesity, glucose intolerance and
hypertension. Percentages of younger (≤60 years old) and older (>60 years
old) donors with one or more of these three conditions were compared by
a chi-square test. A p-value <0.05 was considered significant.
To address the degree to which our donor population represents the national
donor population, we compared RELIVE donors to their complement in the
larger cohort of SRTR donors for donations between 1991 and 2007, where
the comparison SRTR data are at least 90% complete. A second analysis
compared RELIVE and SRTR data for donations between 1995 and 2007,
where the comparison SRTR data are 99% complete.
Statistical analyses were performed with SAS software, version 9.2 (SAS In-
stitute; Cary, North Carolina, USA). The authors have followed the Strength-
ening the Reporting of Observational Studies in Epidemiology (STROBE)
Statement guidelines.
Results
Demographic data are shown in Table 1. The number of
living donors increased substantially at each center over
time, overall nearly tripling from quartile 1 to quartile 2 and
more than doubling from quartile 3 to quartile 4. Females
made up 56% of living kidney donors and there was a trend
on both an absolute and percentile basis for more females
to be donors in recent years. Donors were predominantly
white (86%). Nine percent of living donors were African
American and the majority of these were at the University
of Alabama at Birmingham site, where there was an in-
crease in the proportion of African American donors over
time. Overall, 80% of living kidney donors were biologically
related to their recipient. However, in the most recent quar-
tile (1997–2007), there was an increase in the percentage
of nonbiologically related donors and recipients (Figure 1).
Nonbiologically related donors increased from 1% to 35%
among females and 1% to 29% among males from quar-
tile 1 to quartile 4. Very few donors were nondirected (1%),
and nearly all of those were at the University of Minnesota.
Of note, the cohort predated the use of paired donor ex-
changes at the three participating centers.
The mean age was lowest in quartile 2, and rose in quar-
tiles 3 and 4, reaching 41.5±10.8 years in the most recent
quartile (Table 1 and Figure 2). This trend primarily reflects
an increase in the percentage of donors aged 41– 60 and a
decline in those ≤ 30 years old. Notably, from quartile 2 on,
the percent of donors >60 remained constant at 3% to 4%.
Only 6 of 304 older donors were black. There was a pro-
gressive increase in the percentage of donors who were
former smokers or who never smoked, and a correspond-
ing decrease in the percentage of current smokers. Among
those donating to a first degree biological relative, 77% to
94% indicated a family history of kidney disease and 34%
to 45% indicated a family history of diabetes. However,
these rates may include the donor’s recipient. Rates of
kidney disease or diabetes in first-degree relatives were
lower for donors who were either more distant relatives or
were unrelated to their recipient (3–12%, p < 0.0001 and
20–25%, p < 0.0001, respectively) than rates among first
degree biological relatives.
Additional analyses of trends in predonation characteris-
tics over time are presented in Table 2 and Figure 2. The
American Journal of Transplantation 2013; 13: 390–398 391
Taler et al.
Table 1: General characteristics of kidney donors at time of donation
Era of donation
Quartile 1 Quartile 2 Quartile 3 Quartile 4
(1963–1974) (1975–1985) (1986–1996) (1997–2007) Total
n (%)∗∗
Total 635 (100) 1,715 (100) 2,155 (100) 4,446 (100) 8,951 (100)
Transplant center
Mayo Clinic 167 (26) 300 (17) 351 (16) 1,523 (34) 2,341 (26)
UAB 102 (16) 487 (28) 797 (37) 1,526 (34) 2,912 (33)
UMN 366 (58) 928 (54) 1,007 (47) 1,397 (31) 3,698 (41)
Female 323 (51) 931 (54) 1,228 (57) 2,557 (58) 5,039 (56)
Race
White 580 (91) 1,481 (86) 1,846 (86) 3,820 (86) 7,727 (86)
African American 22 (3) 139 (8) 229 (11) 455 (10) 845 (9)
Other or unknown 33 (5) 95 (6) 80 (4) 171 (4) 379 (4)
Age (Y)∗ 37.1 (11.9) 35.9 (12.0) 39.5 (11.2) 41.5 (10.8) 39.6 (11.5)
≤ 30 228 (36) 702 (41) 534 (25) 811 (18) 2,275 (25)
31 – 40 155 (24) 454 (26) 747 (35) 1,333 (30) 2,689 (30)
41 – 50 153 (24) 304 (18) 516 (24) 1,430 (32) 2,403 (27)
51 – 60 85 (13) 182 (11) 266 (12) 718 (16) 1,251 (14)
> 60 9 (1) 55 (3) 86 (4) 154 (3) 304 (3)
Unknown 5 (1) 18 (1) 6 (0) 0 (0) 29 (0)
Tobacco use
Current 273 (43) 668 (39) 699 (32) 1,235 (28) 2,875 (32)
Former 47 (7) 213 (12) 308 (14) 733 (16) 1,301 (15)
Never 234 (37) 680 (40) 1,094 (51) 2,436 (55) 4,444 (50)
Unknown 81 (13) 154 (9) 54 (3) 42 (1) 330 (4)
Relationship to recipient
Biological 621 (98) 1,692 (99) 1,961 (91) 2,914 (66) 7,188 (80)
Nonbiological 6 (1) 3 (0) 182 (8) 1,459 (33) 1,650 (18)
Anonymous 0 (0) 0 (0) 0 (0) 62 (1) 62 (1)
Unknown 8 (1) 20 (1) 12 (1) 11 (0) 51 (1)
∗ Mean (SD).
∗∗Missing values occurred in age (0.3%), history of tobacco use (0.01%) and relationship to recipient (0.6%).
Figure 1: Total number of
donors and relationship of
donor to recipient by sex.
The number of living donors
increased substantially, from
quartile 1 to quartile 4. There
was a trend on both an ab-
solute and percent basis for
more female donors in recent
years. There was a notable in-
crease in the percentage of
nonbiologically related donors
in the 1997–2007 quartile.
median values for age at donation, BMI, fasting blood glu-
cose and SBP increased over time, while DBP decreased
over the study interval (p < 0.0001 for each, Table 4). Mean
BMI at donation increased progressively from quartile 1 to
4, as did the percentage of living kidney donors meeting
the World Health Organization definition for overweight
(BMI from 25–29.9 kg/m2) and obese (BMI ≥30 kg/m2).
Overall, 20% of all donors had a BMI ≥30 kg/m2. In the
most recent quartile, 26% of donors were obese com-
pared to 8% in quartile 1 (Table 2). Predonation glucose
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Figure 2: Characteristics of living donors by year of donation. Plots of predonation characteristics by year of donation with smoothed
trends (loess curves) over time for each quantile (5th, 25th, 50th, 75th and 95th). Gray circles represent data points. The middle solid
black line represents the median. The black dotted-dashed lines are the 25th and 75th percentiles. The black dotted lines are the 5th and
95th percentiles and the solid grey lines are smoothed through the minima and maxima. The slopes and significance of tests for linear
trends are shown in Table 4.
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Table 2: Metabolic parameters
Era of donation
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N∗∗ (1963–1974) (1975–1985) (1986–1996) (1997–2007) Total
BMI∗ 8,598 24.3 (3.9) 24.7 (4.4) 26.2 (4.6) 27.3 (4.8) 26.4 (4.7)
n (%)
< 25 333 (52) 965 (56) 891 (41) 1,524 (34) 3,713 (41)
25 – 29.9 143 (23) 467 (27) 768 (36) 1,734 (39) 3,112 (35)
30 – 34.9 43 (7) 137 (8) 298 (14) 868 (20) 1,346 (15)
35 – 39.9 8 (1) 30 (2) 83 (4) 226 (5) 347 (4)
≥ 40 0 (0) 10 (1) 14 (1) 56 (1) 80 (1)
Unknown 108 (17) 106 (6) 101 (5) 38 (1) 353 (4)
Glucose∗ 8,298 86.0 (13.0) 94.2 (14.2) 94.9 (16.2) 93.5 (13.5) 93.5 (14.4)
< 100 403 (63) 1,160 (68) 1,382 (64) 3,273 (74) 6,218 (69)
100–125 48 (8) 300 (17) 466 (22) 1,016 (23) 1,830 (20)
126–139 5 (1) 31 (2) 50 (2) 56 (1) 142 (2)
≥ 140 2 (0) 27 (2) 39 (2) 40 (1) 108 (1)
Unknown 177 (28) 197 (11) 218 (10) 61 (1) 653 (7)
Cholesterol∗ 4,251 209.1 (41.3) 194.0 (41.9) 195.5 (38.1) 194.4 (37.2) 195.1 (38.3)
Triglycerides∗ 4,358 108.2 (71.9) 116.7 (64.1) 123.9 (71.9) 124.3 (75.0) 122.4 (72.6)
∗ Mean (SD).
∗∗Missing values occurred in cholesterol (490 (77%) in 1963–1974, 1,063 (62%) in 1975–1985, 1,294 (60%) in 1986–1996 and 1,853
(42%) in 1997–2007) and triglyercides (497 (78%) in 1963–1974, 963 (56%) in 1975–1985, 1,274 (59%) in 1986–1996 and 1,859 (42%)
in 1997–2007).
intolerance increased from 9% in quartile 1 to 21% in quar-
tile 2 and was present in almost one-quarter of living donors
thereafter. There was no statistically significant change in
median cholesterol, triglycerides, or creatinine. There were
changes in the maximum values over time, which trended
upward for each characteristic except creatinine (Table 4
and Figure 2).
We also assessed the presence of one or more of the
following conditions: obesity, glucose intolerance and hy-
pertension in two donor age groups (≤ 60 and > 60 years)
(Figure 3). The prevalence of obesity was similar in donors
≤60 years and those >60 years (20% vs. 17%, respec-
tively; p = 0.1772). Glucose intolerance and hypertension
were both significantly less prevalent in donors ≤ 60 years
than >60 years (20% vs. 43%, p < 0.0001 and 6% vs.
26%, p < 0.0001, respectively). The proportion of donors
with more than one of these three conditions was signif-
icantly higher among the older donors (21% vs. 8%, p <
0.0001). Sixty-two percent of the younger donors and 39%
of the older donors had none of these three conditions, 7%
and 17% had two, and 1% and 4% had all three conditions,
respectively.
Among donors 60 years of age and younger, the percent-
age with obesity, glucose intolerance, hypertension, or a
combination of these conditions differed by sex. Younger
male donors were more likely to have hyperglycemia only,
while younger female donors were more likely to have
none of the three conditions (p < 0.0001). Obesity, glucose
intolerance and hypertension prevalence did not differ by
sex among donors older than 60 (p = 0.064). Black donors
aged 60 years and under were more likely than younger
nonblack donors to be obese only or to have both obesity
and hyperglycemia; younger nonblack donors were more
likely to have none of the three conditions (p < 0.0001).
There were only 6 black donors older than age 60, of whom
4 had one or more of obesity, glucose intolerance and hy-
pertension (1 with one, 2 with two, 1 with three character-
istics). The mean predonation systolic blood pressure (SBP)
increased over time, primarily for male and black donors;
mean diastolic blood pressure (DBP) decreased from quar-
tile 1 to quartile 3 primarily for female donors (Table 3). A
minority of accepted donors (n = 230) were taking antihy-
pertensive medications at the time of donation, and 78%
of these donated after 1997. The overwhelming majority
(92%) of treated hypertensive donors had a SBP <140
mmHg, and 5 had a DBP ≥90 mm Hg.
Comparison of the RELIVE donor population to non-RELIVE
donors in SRTR data during the time period from 1991–
2007, or restricted to 1995–2007 where the comparison
data were 99% complete, indicated similar characteris-
tics (data not shown). Linear trends in age, sex and race
were not different between donors at RELIVE centers and
donors in non-RELIVE centers. We were not able to com-
pare BMI since it was missing for 42% of the SRTR sample.
Discussion
In this large cohort of living kidney donors, we observed
notable trends in donor characteristics over the last five
decades: the number of living kidney donors at the three
study centers increased steadily over time, there was a
marked rise in the proportion of donors unrelated to their
394 American Journal of Transplantation 2013; 13: 390–398
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Table 3: Blood pressure
Era of donation
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N∗∗ (1963–1974) (1975–1985) (1986–1996) (1997–2007) Total
n(%)
Hypertension
No 591 (93) 1,633 (95) 2,036 (94) 4,081 (92) 8,341 (93)
Yes 44 (7) 82 (5) 119 (6) 365 (8) 610 (7)
SBP∗ 8,741 114.9 (12.5) 110.2 (12.0) 112.3 (13.3) 116.4 (13.0) 114.1 (13.1)
< 120 339 (53) 1,226 (71) 1,467 (68) 2,617 (59) 5,649 (63)
120–139 198 (31) 370 (22) 581 (27) 1,615 (36) 2,764 (31)
≥ 140 28 (4) 38 (2) 77 (4) 185 (4) 328 (4)
Unknown 70 (11) 81 (5) 30 (1) 29 (1) 210 (2)
DBP∗ 8,741 72.2 (9.0) 69.1 (8.9) 67.2 (9.8) 67.7 (9.5) 68.1 (9.5)
< 70 151 (24) 705 (41) 1,139 (53) 2,464 (55) 4,459 (50)
70–89 392 (62) 891 (52) 945 (44) 1,910 (43) 4,138 (46)
≥ 90 22 (3) 38 (2) 41 (2) 43 (1) 144 (2)
Unknown 70 (11) 81 (5) 30 (1) 29 (1) 210 (2)
SBP in treated donors∗ 230 119.8 (5.2) 115.2 (12.6) 117.2 (14.1) 123.5 (13.1) 122.0 (13.3)
< 120 4 (67) 10 (48) 13 (57) 59 (33) 86 (37)
120–139 2 (33) 11 (52) 7 (30) 105 (58) 125 (54)
≥ 140 0 (0) 0 (0) 3 (13) 16 (9) 19 (8)
DBP in treated donors∗ 230 78.0 (4.2) 74.0 (9.4) 71.0 (9.7) 72.8 (8.8) 72.9 (8.9)
< 70 0 (0) 6 (29) 9 (39) 51 (28) 66 (29)
70–89 6 (100) 15 (71) 13 (57) 125 (69) 159 (69)
≥ 90 0 (0) 0 (0) 1 (4) 4 (2) 5 (2)
∗ Mean (SD).
∗∗Missing values occurred in systolic and diastolic blood pressure (2.3% overall) but not among donors known to be treated with
medication for hypertension.
Table 4: Relation between living donor characteristics and year of donation, per 10 year increase
5th percentile 25th percentile 50th percentile 75th percentile 95th percentile
Estimate p-Value Estimate p-Value Estimate p-Value Estimate p-Value Estimate p-Value
Age at donation 1.55 <0.0001 2.88 <0.0001 2.87 <0.0001 1.43 <0.0001 0.51 0.0133
BMI 0.56 <0.0001 0.90 <0.0001 1.14 <0.0001 1.26 <0.0001 1.33 <0.0001
Systolic BP 2.00 <0.0001 2.00 <0.0001 1.74 <0.0001 1.62 <0.0001 2.42 <0.0001
Diastolic BP −1.25 0.0008 −0.67 0.0461 −0.77 <0.0001 −1.35 <0.0001 −0.56 0.0558
Fasting blood glucose 0.38 0.1695 1.07 <0.0001 1.18 <0.0001 0.71 0.0002 −1.36 0.1276
Cholesterol 0.71 0.4591 0.00 1.0000 0.00 1.0000 −2.31 0.0066 −7.20 <0.0001
Triglycerides 0.67 0.3041 0.34 0.5633 0.29 0.7973 1.61 0.2550 11.82 0.0217
Serum creatinine −0.00 0.0011 −0.00 <0.0001 −0.01 0.1212 −0.00 1.0000 −0.00 1.0000
recipient, and a higher proportion of female donors. While
the mean age at donation increased, donors > 60 years
constituted a stable minority of up to 4% over the period
studied.
We observed trends over time toward higher values in the
upper end of the distributions of all characteristics reported
except serum creatinine. In contrast, mean values for fast-
ing blood glucose and blood pressure changed little over
time. In terms of applying a label of glucose intolerance to
measured blood glucose values or a label of hypertension
to blood pressure measurements, the use of both older
and more contemporary label definitions demonstrated
fairly stable donor acceptance practice across the most
recent three time quartiles. There were very few donors
(1%–2%) with fasting blood glucose above 125 mg/dL in
any quartile. While an increasing number of programs re-
ported willingness to accept hypertensive donors, particu-
larly older ones, practices among the three RELIVE study
sites extended only to those with milder forms of hyper-
tension. The majority of recorded blood pressure measure-
ments were below 140/90 mm Hg, and these donors may
have been accepted after factoring in measurement cir-
cumstances (e.g. white coat hypertension) that were not
available for analysis. Ambulatory blood pressure monitor-
ing was not performed in earlier years or at all centers.
While it would be misleading to label an individual as hyper-
tensive by a single reading, even using the highest of three
possible recorded blood pressure values, there was not a
trend toward higher predonation blood pressure over time.
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A. Donors ≤ 60 years (N = 8,647):  


























Figure 3: Clustering of obesity, glu-
cose intolerance and hypertension.
Donors are categorized into groups
based on predonation BMI ≥ 30 kg/m2,
fasting blood glucose > 100 mg/dL and
diagnosis of hypertension using Venn di-
agrams and compared by age (younger
≤60 years old and older >60 years old)
using the chi-square test. The overall Chi-
square statistic is significant (x2 = 318.2,
p < 0.0001), indicating the clustering of
obesity, glucose intolerance and hyper-
tension differs by age category.
The national trend of an increasing prevalence of obesity
in the general population as reported in NHANES (15) is
clearly mirrored among donors. It is notable that 26% of
all donors had a BMI ≥ 30 kg/m2 in the most recent era
compared to 8% in 1963–1974. We believe some of those
donors were accepted after careful evaluation, based on
the absence of other adverse metabolic conditions or were
muscular in build. Similarly, 22% of donors in the most
recent era had glucose intolerance compared to 7% in
1963–1974. The acceptance of donors with recorded glu-
cose measurements clearly outside of acceptable range
for any era does raise concerns. There may have been
additional normal values documented by a local provider,
but not captured by our abstraction approach. While choles-
terol and triglyceride levels were relatively stable over time,
there were fewer donors with high cholesterol values and
more donors with high triglyceride levels, tracking with
increased BMI.
The lifetime risk of hypertension is very high in the general
population. Hypertension prevalence increases with age in
Western societies and the treatment is generally effective
and well accepted. In fact, one’s risk of developing this
condition, even if normotensive at age 55, is around 90%
by age 80 (16). This is of great relevance, particularly to
the younger donor, as optimal health at a young age does
not guarantee continued health decades later, particularly
if the young donor does not adopt healthy lifestyle prac-
tices. Reports of higher hypertension prevalence rates in
donors (17) or of incrementally higher blood pressure after
living kidney donation (18) may reflect earlier occurrence,
or earlier detection and treatment. It is reassuring to see
that only 6% of donors 60 years and younger were hyper-
tensive in contrast to 26% of those over 60.
We did observe greater tolerance for multiple potential risk
conditions in donors over age 60. A minority of even these
older donors had all three conditions of obesity, glucose
intolerance and hypertension, but 61% had at least one,
compared to 38% of donors age 60 or lower. We conclude
that these transplant centers were potentially willing to
tolerate one or two of these conditions primarily in the
older donor but less commonly would accept all three.
Stricter criteria appear to be applied to younger donors,
with lower percentages with even a single risk factor for
CKD, in particular hypertension or glucose intolerance.
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Data on acceptance of donors with isolated medical ab-
normalities (IMAs) are limited, often to small case series.
A systematic review identified 37 reports, each including
at least three donors with IMAs; seven of these were re-
ported only as abstracts (9). Twenty-two studies included
older donors, ten studies obese donors and six studies
hypertensive donors. Whether there is a trend to greater
acceptance of donors with IMAs was not clear from prior
analyses, as results were not stratified by donation era and
definitions were not standardized. Our results illustrate
that the trend of increasing obesity seen in the general
population is reflected in accepted donors but also indi-
cate stable rates of glucose intolerance or hypertension in
donors, likely related to the continuation of previous accep-
tance criteria despite adoption of lower numerical thresh-
olds for diagnosis of these conditions in other settings.
Still, the inclusion of donors with elevated blood pressure
or hyperglycemia merits review and reinforces the need
for follow-up.
This study was limited by the use of cross-sectional data
not collected specifically for research purposes and not
verified at the time of collection. Comparison of RELIVE
donors to the national donor population recorded by the
SRTR suggests that the donor trends seen in RELIVE
were not different from the larger SRTR cohort. We may
have overestimated the prevalence of predonation hyper-
tension. We recorded up to three readings, but measure-
ment techniques have changed over time and we could
not document use of inappropriate cuff size given the ret-
rospective study design. We did not have sufficient infor-
mation on ambulatory blood pressure measurements to
exclude white coat hypertension that may have been oth-
erwise ascertained by the evaluating teams. Similarly, we
recorded the glucose value closest to but prior to donation.
We did not record glucose measurements done locally or
at the center prior to the preoperative visit that may have
been taken under strict fasting conditions. There could
have been additional values that were normal that were
taken into consideration in the process of donor approval.
Data on hemoglobin A1c or glycosylated hemoglobin were
available in only 767 (8.6%) cases. They were mostly nor-
mal. Oral glucose tolerance testing was not used routinely
across centers, and we did not record this information.
With three centers located in two geographic regions of
the United States, we chose to analyze our data as an ag-
gregated cohort. We examined only the characteristics of
actual donors and cannot assess acceptance rates among
those who presented as potential donors. With only three
centers, we could not comprehensively analyze center-
based practice variation.
Living donors have historically been held to a higher health
standard than that of the general population, both to ensure
long-term health and stability for the donor and to protect
the recipient from transplantation with a less than optimal
organ. As the transplant candidate population ages, they
may have fewer healthy prospective living donors avail-
able, resulting in consideration of those with isolated im-
perfections. If an organ with fewer potential future years
of function is to be transplanted into an older recipient
with a shorter remaining lifespan, organ function may be
adequate to serve both donor and recipient over their re-
maining years of life. Furthermore, as most renal diseases
present in mid-life or later, thorough evaluation of a young
individual does not necessarily provide clues or guarantee
protection from the later onset of disease. Based on our
data and those reported by others, tolerance for associ-
ated medical risk factors among young donors has been
reported to be declining (19), perhaps contributing to a
greater willingness to consider imperfections among older
donor candidates with fewer future years at risk for late
complications of donation. Short- and mid-term reports re-
garding outcomes for hypertensive (20) and obese (21)
donors suggest that these donors have similar outcomes
to donors without these conditions.
Living kidney donation experienced explosive growth over
the study period, with greater use of donors between the
ages of 41 and 60 years and of obese donors. At the same
time, utilization of donors with hypertension or glucose
intolerance by current definitions is not new and in fact
has remained steady. While the percentage of hyperten-
sive donors was 5% to 8%, glucose intolerance was more
common, affecting 19% to 24% of donors from 1975 on.
The percent of donors age 30 years and younger declined
from 41% to 18%, while the percentage of donors older
than 60 remained low at 3% to 4%. A possible explanation
for these trends is greater focus by transplant programs on
long-term outcomes for living kidney donors with perhaps
lower inclination to accept young donors due to uncertain-
ties regarding their lifetime risk for future diseases. Stable
and limited acceptance of older donors, donors with obe-
sity or glucose intolerance, and hypertensive donors sup-
ports the adoption of thoughtful individual case review in
the donor approval process.
Taken together, this combined data set from three large
transplant centers indicates that the overwhelming major-
ity of accepted donors met consistent glucose tolerance
and blood pressure criteria. In fact, with the exception of
age and BMI, there were only minimal changes observed
for most medical characteristics of living kidney donors
over the course of the last five decades. We did see an
increase in the maximal values for all reported parameters,
highlighting the need for prospective data collection and
long-term follow-up.
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